Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
2.86M
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
1.28M
-
Shares change
-
-680K
-
Total reported value, excl. options
-
$231K
-
Value change
-
-$296K
-
Number of buys
-
9
-
Number of sells
-
-8
-
Price
-
$0.18
Significant Holders of Aptevo Therapeutics Inc. - Common Stock, $0.001 par value (APVO) as of Q3 2024
23 filings reported holding APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value as of Q3 2024.
Aptevo Therapeutics Inc. - Common Stock, $0.001 par value (APVO) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.28M shares
of 2.86M outstanding shares and own 44.8% of the company stock.
Largest 10 shareholders include Hudson Bay Capital Management LP (936K shares), CITADEL ADVISORS LLC (112K shares), GEODE CAPITAL MANAGEMENT, LLC (43.7K shares), Virtu Financial LLC (42K shares), RENAISSANCE TECHNOLOGIES LLC (36.6K shares), HRT FINANCIAL LP (28.1K shares), TWO SIGMA SECURITIES, LLC (28K shares), Tower Research Capital LLC (TRC) (25.1K shares), JANE STREET GROUP, LLC (17.2K shares), and TWO SIGMA INVESTMENTS, LP (14.2K shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.